drugset / Trial / NCT07219420

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Palmoplantar Pustulosis

NCT07219420

Phase 3 Recruiting 320 enrolled UCB Biopharma SRL
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of bimekizumab compared with placebo in participants with palmoplantar pustulosis (PPP).

Timeline

Start
2025-11-14
Primary completion
2027-12-27
Completion
2029-11-22

Drugs

EvaluationDrugModalityDoseRoute
Subject Bimekizumab Monoclonal antibody